Shijiazhuang Keren Pharmaceutical Technology

Shijiazhuang Keren Pharmaceutical Technology is a clinical-stage biopharmaceutical company based in Shijiazhuang, China, dedicated to the discovery and development of innovative therapies for metabolic and autoimmune diseases. The company leverages its expertise in small molecule and peptide chemistry to build a robust pipeline of candidates targeting high-value mechanisms. Its lead asset, KR-011, is a selective JAK1 inhibitor currently undergoing Phase 2 clinical evaluation for rheumatoid arthritis and atopic dermatitis. Other key programs include KR-001, a GLP-1 receptor agonist for metabolic disorders, and KR-022, a URAT1 inhibitor for the treatment of gout. Keren Pharmaceutical aims to provide effective and accessible treatment options for patients with chronic inflammatory and metabolic conditions.